## Special Issue

## Advances in Diagnosis and Treatment of Peritoneum Cancer

## Message from the Guest Editors

Nearly 4-10% of patients with tumors of the abdominal cavity have Peritoneal Metastasis at the time of diagnosis, and 20-40% will develop PM during their evolution. Until recently the diagnosis of PM was ominous and associated with severe and incapacitating symptoms, poor response to systemic chemotherapy, and poor survival of 4-6 months after diagnosis. The scenario has changed after the introduction of the new generation of chemotherapy and the agents against biological targets and with the introduction of new combined therapies: cytoreductive surgery, and new diagnostic-therapeutic schemes. However, there are still many unresolved issues with respect to the role, indications and efficiency that these new therapeutic schemes may offer. In this Special Issue of JCM we aim to evaluate the latest knowledge in PM with respect to incidence, clinical and molecular prognostic factors, survival, and the role of surgical-chemotherapeutic techniques in this era of biological and immunotherapy agents. Special interest will be focused in colorectal, gastric, ovarian cancer and primary peritoneal cancer.

### **Guest Editors**

Dr. Manuel Diez-Alonso

Department of General Surgery, Príncipe de Asturias University Hospital, 28801 Alcalá de Henares, Spain

Dr. Alberto Gutierrez-Calvo

Department of General Surgery, Príncipe de Asturias University Hospital, 28801 Alcalá de Henares, Spain

### Deadline for manuscript submissions

closed (20 January 2024)



# Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/130277

Journal of Clinical Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcm@mdpi.com

mdpi.com/journal/

jcm





# Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9 CiteScore 5.2 Indexed in PubMed





## About the Journal

## Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

## **Editors-in-Chief**

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### **Journal Rank:**

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).